Skip to content

Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis

Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06737952
Enrollment
90
Registered
2024-12-17
Start date
2025-05-31
Completion date
2029-12-31
Last updated
2025-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Arthritis, Rheumatoid, Osteoarthritis, Spondyloarthritis, Synovitis

Keywords

ultrasound-guided synovial biopsies (UGSB), inflammatory response, synovial biopsy

Brief summary

This study aims to study the inflammatory response in various forms of arthritis.

Detailed description

Arthritis, a significant heald burden is characterized by joint inflammation that severely impacts patients' quality of live. Despite advancements in treatment, many individuals with conditions like rheumatoid arthritis (RA), osteoarthritis (OA), and spondyloarthritis (SpA) do not achieve satisfactory outcomes, underscoring the need for more precise therapeutic strategies. The project aims to characterize the inflammatory response in various form of arthritis by collecting and analyzing synovial tissue-the connective tissue lining joints. Biopsies will be collected through ultrasound-guided biopsies (UGSB), a minimally invasive and well-tolerated procedure. Presence of immune and stromal cells in the tissue, their interactions, and their relationship to clinical symptoms are characterized by histological and molecular methods. By comparing these features across different forms of arthritis, the study aims to identify molecular pathways and biomarkers that distinguish these diseases and their subtypes. The study hopes to contribute to a broader understanding of arthritis pathophysiology, ultimately translating into novel therapeutic targets and tailored clinical strategies.

Interventions

None listed

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * Clinically relevant arthritis in one or more joints as assessed by the treating rheumatologist, including RA, SpA, connective tissue disease and OA.

Exclusion criteria

* Known allergies to local anesthetics * Family history of bleeding, history of increased bleeding tendency or prolonged bleeding, current treatment with oral anticoagulants or platelet aggregation inhibitors; Quick \< 65%, international normalised ratio (INR) ≥ 1.3, thrombocyte count \< 100'000/μl, activated partial thromboplastin time (aPTT) \> 37 sec * Inability or insufficient knowledge of project language to understand the information given in the informed consent form

Design outcomes

Primary

MeasureTime frameDescription
Grade of synovitisimmediately after collection to study completion, up to 5 yearsassessed by the Krenn score in the hematoxylin and eosin staining (Score 0-3, 0=normal, 3=severe)
classification pathotypesimmediately after collection to study completion, up to 5 yearsimmunohistochemical staining with cell type specific markers including CD15, CD68, CD3, CD20, CD138 of the collected tissues from different arthritis subtypes
comparing transcriptomic signatureimmediately after collection to study completion, up to 5 yearssingle-cell RNA sequencing of collected tissues from different arthritis subtypes to identify disease specific biomarkers.

Contacts

Primary ContactDiego Kyburz, Prof. Dr.
diego.kyburz@usb.ch+41 61 328 74 81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026